
ORIC Pharmaceuticals ORIC
$ 13.82
2.75%
Annual report 2025
added 02-23-2026
ORIC Pharmaceuticals Shares 2011-2026 | ORIC
Annual Shares ORIC Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 87.8 M | 69.7 M | 51.5 M | 39.7 M | 38 M | 30.3 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 87.8 M | 30.3 M | 52.8 M |
Quarterly Shares ORIC Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 99 M | 78.1 M | 71 M | 71 M | 70.5 M | 70.3 M | 67.3 M | 54.9 M | 57.4 M | 45.7 M | 45.1 M | 45.1 M | 39.6 M | 39.5 M | 39.4 M | 39.4 M | 39 M | 36.7 M | 36.7 M | 36.7 M | 30.3 M | 21.6 M | 1.99 M | 1.98 M | 1.95 M | 1.87 M | 1.81 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 99 M | 1.81 M | 42.4 M |
Shares of other stocks in the Biotechnology industry
| Issuer | Shares | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M | ||
|
Alector
ALEC
|
103 M | $ 2.19 | -9.77 % | $ 226 M | ||
|
Acer Therapeutics
ACER
|
15.8 M | - | 2.71 % | $ 14 M | ||
|
I-Mab
IMAB
|
187 M | - | - | $ 866 M | ||
|
Cabaletta Bio
CABA
|
1.17 M | $ 3.34 | 0.45 % | $ 3.9 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | ||
|
AgeX Therapeutics
AGE
|
1.08 K | - | -10.17 % | $ 12.2 K | ||
|
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M | ||
|
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | ||
|
Codexis
CDXS
|
73.4 M | $ 1.02 | 1.49 % | $ 74.9 M | ||
|
AbCellera Biologics
ABCL
|
299 M | $ 3.74 | 3.6 % | $ 1.12 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | ||
|
Cerus Corporation
CERS
|
185 M | $ 2.6 | 1.37 % | $ 480 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M | ||
|
Cellectis S.A.
CLLS
|
44.8 M | $ 3.87 | -0.39 % | $ 116 M | ||
|
ARCA biopharma
ABIO
|
16.8 M | - | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
1.24 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
12.1 M | - | 4.01 % | $ 150 M | ||
|
CNS Pharmaceuticals
CNSP
|
382 K | $ 3.23 | 2.22 % | $ 1.23 M | ||
|
Adverum Biotechnologies
ADVM
|
19.8 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - | ||
|
AIkido Pharma
AIKI
|
6.18 M | - | 1.93 % | $ 17.4 M | ||
|
Collegium Pharmaceutical
COLL
|
31.7 M | $ 41.75 | 0.19 % | $ 1.32 B | ||
|
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
34.4 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
19.2 M | - | -0.23 % | $ 916 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
104 M | $ 36.14 | 1.23 % | $ 3.75 B | ||
|
Allena Pharmaceuticals
ALNA
|
68 M | - | 3.16 % | $ 1.9 M | ||
|
Amarin Corporation plc
AMRN
|
408 M | $ 13.98 | 1.27 % | $ 5.7 B | ||
|
Aileron Therapeutics
ALRN
|
17.9 M | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
5.01 M | - | 4.14 % | $ 49.1 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
122 M | $ 23.77 | 2.99 % | $ 2.91 B | ||
|
Alpine Immune Sciences
ALPN
|
33.4 M | - | - | $ 2.17 B | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
4.33 M | $ 8.41 | -1.87 % | $ 36.4 M | ||
|
Cardiff Oncology
CRDF
|
66.8 M | $ 1.94 | 0.01 % | $ 130 M | ||
|
Curis
CRIS
|
6.31 M | $ 1.1 | -3.51 % | $ 6.94 M | ||
|
Aeterna Zentaris
AEZS
|
115 M | - | 5.93 % | $ 314 M | ||
|
CorMedix
CRMD
|
50.9 M | $ 7.16 | 0.42 % | $ 364 M | ||
|
Ampio Pharmaceuticals
AMPE
|
810 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
38.8 M | - | - | $ 10.1 M | ||
|
Champions Oncology
CSBR
|
13.7 M | $ 6.14 | 3.89 % | $ 83.9 M | ||
|
Aravive
ARAV
|
36.4 M | - | -13.39 % | $ 1.45 M | ||
|
Aptose Biosciences
APTO
|
699 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
67.7 M | - | -39.0 % | $ 4.57 M | ||
|
Citius Pharmaceuticals
CTXR
|
6.73 M | $ 0.72 | -2.34 % | $ 4.84 M | ||
|
Athira Pharma
ATHA
|
38.5 M | - | - | $ 269 M | ||
|
Aridis Pharmaceuticals
ARDS
|
18.8 M | - | 17.91 % | $ 11.1 M | ||
|
Altimmune
ALT
|
71 M | $ 4.21 | -2.32 % | $ 299 M | ||
|
CEL-SCI Corporation
CVM
|
63.8 M | $ 3.88 | -8.92 % | $ 247 M |